Clinical Trials


Safety, PK and PD Study of ABX464 in Untreated HIV Patients

This study has been completed
Abivax S.A.

Information provided by (Responsible Party)
Abivax S.A. Identifier

First received: April 10, 2015
Last updated: May 27, 2016
Last Verified: May 2015
History of Changes


ABX464 is a first in class that showed efficacy as an anti-HIV therapy. The present study is intended to assess the safety, the tolerability, and pharmacokinetic parameters and to evaluate the effect on viral load of repeated oral administrations of ABX464 in patients infected by HIV, not previously treated for their HIV.

Two types of design are intended in this protocol: dosing every 3 days or dosing every day. The goal is to determine the best dosing regimen to reduce viral load and minimize adverse events.

Condition Intervention Phase
Human Immunodeficiency Virus Infections

Drug : ABX464
Other : Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Dose Escalation, Schedule Comparison Study to Evaluate the Safety, Pharmacokinetics, and Viral Kinetics of ABX464 in Untreated Patients With HIV Infection in Mauritius

Further study details as provided by Abivax S.A.:

Primary Outcome Measures

  • Safety and tolerability profile of ABX464 as assessed by the change from baseline in laboratory values, in vital signs and ECG parameters at week 3 and by the number of patients with adverse events. [ Time Frame: Week 3 ]
    Number of patients with abnormal blood (hematology and biochemistry) and urinary laboratory values, abnormal vital signs and ECG parameters and the number/proportion of patients reporting any adverse event.
Secondary Outcome Measures:
  • Cmax [ Time Frame: week 1, week 2 and week 3 ]
    Maximum concentration in plasma of ABX464 and metabolite
  • tmax [ Time Frame: Week 3 ]
    Time to maximum concentration
  • AUC [ Time Frame: Week 3 ]
    Area under the concentration-time curve
  • t1/2 [ Time Frame: Week 3 ]
    Half-life of the ABX464 in plasma
  • Pharmacodynamic activity as expressed by CD4 and CD8 count [ Time Frame: Week 3 ]
    CD4 and CD8 values
  • Pharmacodynamic activity as expressed by HIV viral load [ Time Frame: Week 3 ]
    HIV viral load across time and possible relationship with PK parameters

Enrollment: 70
Study Start Date: January 2015
Study Completion Date: May 2016
Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: ABX464

Drug: ABX464

25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks

Placebo Comparator: Placebo

Other: Placebo

1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks



Ages Eligible for Study: 18 Years to 65 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria:

    1. Males or females, 18 to 65 years of age
    2. Patients infected by HIV-1 or HIV-2
    3. BMI between 17 and 29 kg/m².
    4. CD4 cell count ≥ 350 /mm3 and HIV RNA level between 5,000-500,000 copies/mL.
    5. Clinical laboratory tests (hematology, blood chemistry, and urinalyses) must be within normal limits, or clinically acceptable to the sponsor and principal investigator and consistent with the underlying HIV infection.
    6. Urine drug screen for drugs with a high potential for abuse (cocaine, opiates, amphetamines and barbiturates) and alcohol breath test must be negative.
    7. Females must be non lactating and either be of nonchildbearing potential (ie sterilized via hysterectomy or bilateral tubal ligation or at least one year post-menopausal) or if of child bearing potential, must be practicing effective double barrier contraceptive methods from at least two weeks prior to Day 1 until 3 months after the last dose of study medication.
    8. Males must practice an effective barrier method of contraception from Day 1 until 3 months days after the last dose of study medication.
    9. Patients must be willing to give written informed consent prior to study enrollment and be able to adhere to restrictions and examination schedules.
    10. Physical examination and ECG must be within normal limits.
    11. Never taken any antiretroviral agent except for a brief time, and for some reasons, the patient decided not to continue therapy (i.e. Toxicity, personal decision. None in past 30-180 days.

Exclusion Criteria:
    1. Individuals with a history of any significant medical disorders which requires a physician's care.
    2. Individuals who have a history of any clinically significant local or systemic infectious disease (other than HIV-1 or HIV-2 infection) within four weeks prior to drug administration.
    3. Individuals with any clinically significant laboratory abnormalities as defined as grade 2 or 3 in Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.
    4. Individuals who are positive for hepatitis B virus and/or hepatitis C virus
    5. Any individual who does not comply with the requirement that he should not have used any drugs (including prescription, nonprescription, herbal, and mineral supplements) other than paracetamol for at least two weeks prior to the study nor alcohol within 48 hours prior to drug administration and for the entire study period. The use of a concomitant medications to treat an AE during the study will not be considered a protocol violation.
    6. Individuals who have participated in a clinical trial of an investigational drug within 90 days prior to the start of the study
    7. Individuals who smoke more than ten cigarettes or equivalent tobacco use per day.
    8. Individuals with forfeiture of freedom by an administrative or legal obligation or
    under guardianship

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02452242


CAP Research Ltd
Curepipe, Mauritius
HIV-NAT, Thai Red Cross AIDS Research Center
Bangkok, Thailand, 10330
Siriraj Hospital, Mahidol University
Bangkok, Thailand, 10700
Chiang Mai University
Chiang Mai, Thailand, 50200

Sponsors and Collaborators

Abivax S.A.
More Information

More Information

Responsible Party: Abivax S.A. Identifier: NCT02452242   History of Changes  
Other Study ID Numbers: ABX464-003  
Study First Received: April 10, 2015  
Last Updated: May 27, 2016  

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections processed this data on June 02, 2020
This information is provided by